Certara price target raised to $20 from $17 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Certara to $20 from $17 and keeps an Overweight rating on the shares. The analyst says 2023 will likely be a "tale of 2 cities" for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.